131 related articles for article (PubMed ID: 9052747)
1. Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours.
Shih YC; Kerr J; Liu J; Hurst T; Khoo SK; Ward B; Wainwright B; Chenevix-Trench G
Int J Cancer; 1997 Mar; 70(5):508-11. PubMed ID: 9052747
[TBL] [Abstract][Full Text] [Related]
2. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma.
Hamada K; Kohno T; Kawanishi M; Ohwada S; Yokota J
Genes Chromosomes Cancer; 1998 Jul; 22(3):232-40. PubMed ID: 9624535
[TBL] [Abstract][Full Text] [Related]
3. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population.
Biden K; Young J; Buttenshaw R; Searle J; Cooksley G; Xu DB; Leggett B
Hepatology; 1997 Mar; 25(3):593-7. PubMed ID: 9049204
[TBL] [Abstract][Full Text] [Related]
4. Frequent loss of heterozygosity in early non-small cell lung cancers at chromosome 9p21 proximal to the CDKN2a gene.
Mead LJ; Gillespie MT; Hung JY; Rane US; Rayeroux KC; Irving LB; Campbell LJ
Int J Cancer; 1997 Apr; 71(2):213-7. PubMed ID: 9139845
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A gene inactivation in epithelial sporadic ovarian cancer.
Niederacher D; Yan HY; An HX; Bender HG; Beckmann MW
Br J Cancer; 1999 Aug; 80(12):1920-6. PubMed ID: 10471040
[TBL] [Abstract][Full Text] [Related]
6. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
7. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
Suzuki H; Zhou X; Yin J; Lei J; Jiang HY; Suzuki Y; Chan T; Hannon GJ; Mergner WJ; Abraham JM
Hum Mol Genet; 1995 Oct; 4(10):1883-7. PubMed ID: 8595411
[TBL] [Abstract][Full Text] [Related]
8. Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2.
Schultz DC; Vanderveer L; Buetow KH; Boente MP; Ozols RF; Hamilton TC; Godwin AK
Cancer Res; 1995 May; 55(10):2150-7. PubMed ID: 7743516
[TBL] [Abstract][Full Text] [Related]
9. LOH and mutation analysis of CDKN2 in primary human ovarian cancers.
Campbell IG; Foulkes WD; Beynon G; Davis M; Englefield P
Int J Cancer; 1995 Oct; 63(2):222-5. PubMed ID: 7591208
[TBL] [Abstract][Full Text] [Related]
10. Chromosome 9p deletions in invasive and noninvasive nonfunctional pituitary adenomas: the deleted region involves markers outside of the MTS1 and MTS2 genes.
Farrell WE; Simpson DJ; Bicknell JE; Talbot AJ; Bates AS; Clayton RN
Cancer Res; 1997 Jul; 57(13):2703-9. PubMed ID: 9205080
[TBL] [Abstract][Full Text] [Related]
11. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma.
Takita J; Hayashi Y; Kohno T; Yamaguchi N; Hanada R; Yamamoto K; Yokota J
Cancer Res; 1997 Mar; 57(5):907-12. PubMed ID: 9041193
[TBL] [Abstract][Full Text] [Related]
12. Absence of deletions but frequent loss of expression of p16INK4 in human ovarian tumours.
Marchini S; Codegoni AM; Bonazzi C; Chiari S; Broggini M
Br J Cancer; 1997; 76(2):146-9. PubMed ID: 9231912
[TBL] [Abstract][Full Text] [Related]
13. CDKNA2A mutation analysis, protein expression, and deletion mapping of chromosome 9p in conventional clear-cell renal carcinomas: evidence for a second tumor suppressor gene proximal to CDKN2A.
Schraml P; Struckmann K; Bednar R; Fu W; Gasser T; Wilber K; Kononen J; Sauter G; Mihatsch MJ; Moch H
Am J Pathol; 2001 Feb; 158(2):593-601. PubMed ID: 11159196
[TBL] [Abstract][Full Text] [Related]
14. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas.
Wong DJ; Barrett MT; Stöger R; Emond MJ; Reid BJ
Cancer Res; 1997 Jul; 57(13):2619-22. PubMed ID: 9205067
[TBL] [Abstract][Full Text] [Related]
15. High frequency of chromosome 9 deletion in ovarian cancer: evidence for three tumour-suppressor loci.
Devlin J; Elder PA; Gabra H; Steel CM; Knowles MA
Br J Cancer; 1996 Feb; 73(4):420-3. PubMed ID: 8595153
[TBL] [Abstract][Full Text] [Related]
16. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma.
Caldas C; Hahn SA; da Costa LT; Redston MS; Schutte M; Seymour AB; Weinstein CL; Hruban RH; Yeo CJ; Kern SE
Nat Genet; 1994 Sep; 8(1):27-32. PubMed ID: 7726912
[TBL] [Abstract][Full Text] [Related]
17. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of the INK4a/ARF locus and p53 in sporadic extrahepatic bile duct cancers and bile tract cancer cell lines.
Caca K; Feisthammel J; Klee K; Tannapfel A; Witzigmann H; Wittekind C; Mössner J; Berr F
Int J Cancer; 2002 Feb; 97(4):481-8. PubMed ID: 11802210
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
20. No evidence exists for methylation inactivation of the p16 tumor suppressor gene in ovarian carcinogenesis.
Ryan A; Al-Jehani RM; Mulligan KT; Jacobs IJ
Gynecol Oncol; 1998 Jan; 68(1):14-7. PubMed ID: 9454653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
